Business Context and Reporting Period
Company: Champions Oncology, Inc. (CSBR)
Filing Type: Form 8-K (Current Report)
Report Date: December 11, 2024
Reporting Period: Second Quarter ended October 31, 2024
Context: The filing serves to announce the issuance of a press release containing unaudited financial results for the quarter ended October 31, 2024. The detailed financial data is contained in Exhibit 99.1 (Press Release) and is not embedded within the body of this 8-K text.
Key Financial Metrics
The provided text for this Form 8-K does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the attached press release (Exhibit 99.1) but are not present in the source text provided for this summary.
Material Changes
No material changes or comparative financial data versus prior periods are detailed in the text of this filing. The document solely confirms the release of the Q2 2024 results.
Guidance, Outlook, and Risks
Management Commentary: The filing notes that the information under Item 2.02 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Guidance and Risks: The source text does not provide specific guidance, outlook, risk factors, or details on contingencies and unusual items. These would be located in the referenced press release.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated December 11, 2024) for actual revenue, net loss, and cash position figures.
- Verify the unaudited nature of the financial results as stated in the filing.
- Check for any forward-looking statements or updated clinical trial milestones in the attached press release.
- Confirm the company's cash runway and liquidity status, which are not detailed in the 8-K summary text.